Neurochemical biomarkers in Alzheimer’s disease and related disorders

Therapeutic Advances in Neurological Disorders

Volumn 5, Issue 6, 2012, Pages 335-348

  Bibl, Mirko ^a   Esselmann, Hermann ^a   Wiltfang, Jens ^b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Alzheimer s disease; biomarker; blood; cerebrospinal fluid; dementia

Indexed keywords

ALZHEIMER ASSOCIATED PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E4; BETA SECRETASE; BIOCHEMICAL MARKER; CHOLINESTERASE INHIBITOR; FATTY ACID BINDING PROTEIN; GAMMA SECRETASE INHIBITOR; IMMUNOGLOBULIN; MEMANTINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOPROTEIN; PRESENILIN; PROTEIN; RISPERIDONE; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CREUTZFELDT JAKOB DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DYSPNEA; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FRONTOTEMPORAL DEMENTIA; GENETIC RISK; HUMAN; LUMBAR PUNCTURE; MILD COGNITIVE IMPAIRMENT; MOLECULAR PATHOLOGY; MULTIINFARCT DEMENTIA; NEUROFIBRILLARY TANGLE; POSTDURAL PUNCTURE HEADACHE; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; REVIEW; SENILE PLAQUE; SENSITIVITY AND SPECIFICITY;

EID: 84868244886     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285612455367     Document Type: Article

References (112)

1. Andersen C. Jensen M. Lannfelt L. Lindau M. Wahlund L. (2000) Amyloid Abeta 40 CSF concentrations correlate to frontal lobe atrophy in frontotemporal dementia. Neuroreport 11: 287–290.
2. Andreasen N. Minthon L. Davidsson P. Vanmechelen E. Vanderstichele H. Winblad B. et al. (2001) Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 58: 373–379.
3. Bibl M. Esselmann H. Lewczuk P. Trenkwalder C. Otto M. Kornhuber J. et al. (2010) Combined analysis of CSF tau, Aβ42, Aβ1-42% and Aβ1-40ox% in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Int J Alzheimers Dis pii: 761571.
4. Bibl M. Esselmann H. Mollenhauer B. Weniger G. Welge V. Liess M. et al. (2007 a) Blood-based neurochemical diagnosis of vascular dementia: a pilot study. J Neurochem 103: 467–474.
5. Bibl M. Esselmann H. Mollenbauer B. Wiltfang J. (2006 a) Aminoterminally truncated and oxidized amyloid-beta peptide species in Alzheimer's disease. Neuroscience 143: 461–475.
6. Bibl M. Esselmann H. Otto M. Lewczuk P. Cepek L. Rüther E. et al. (2004) Cerebrospinal fluid (CSF) amyloid beta (Aβ) peptide patterns in Alzheimer's disease (AD) patients and non-demented controls depend on sample pre-treatment: indication of carrier- mediated epitope masking of Aβ peptides. Electrophoresis 25: 2912–2918.
7. Bibl M. Lewczuk P. Esselmann H. Mollenhauer B. Klafki H. Welge V. et al. (2008 a) CSF amyloid-β1-38 and 1-42 in FTD and AD: biomarker performance critically depends on the detergent accessible fraction. Proteomics Clin App 2: 1548–1556.
8. Bibl M. Mollenhauer B. Esselmann H. Lewczuk P. Klafki H. Sparbier K. et al. (2006 b) CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain 29: 1177–1187.
9. Bibl M. Mollenhauer B. Esselmann H. Lewczuk P. Trenkwalder C. Rüther E. et al. (2006 c) CSF diagnosis of Alzheimer's disease and dementia with Lewy bodies. J Neural Transm 114: 621–628.
10. Bibl M. Mollenhauer B. Esselmann H. Schneider M. Lewczuk P. Welge V. et al. (2008 b) Cerebrospinal fluid neurochemical phenotypes in vascular dementias: original data and mini-review. Dement Geriatr Cogn Disord 25: 256–265.
11. Bibl M. Mollenhauer B. Lewczuk P. Esselmann H. Wolf S. Otto M. et al. (2011) Cerebrospinal fluid tau, p-tau 181 and amyloid-β38/40/42 in frontotemporal dementias and primary progressive aphasias. Dement Geriatr Cogn Disord 31: 37–44.
12. Bibl M. Mollenhauer B. Lewczuk P. Esselmann H. Wolf S. Trenkwalder C. et al. (2007 b) Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias. Mol Psy 12: 671–680.
13. Bibl M. Wiltfang J. (2008) Diagnostic and prognostic needs in neurodegenerative diseases: focus on proteomics. Expert Rev Proteomics 5: 153–156.
14. Billingsley M. Kincaid R. (1997) Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. Biochem J 323: 577–591.
15. Blennow K. (2004) Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 1: 213–225.
16. Blennow K. de Leon M. Zetterberg H. (2006) Alzheimer's disease. Lancet 368: 387–403
17. Blennow K. Wallin A. Agren H. Spenger C. Siegfried J. Vanmechelen E. (1995) Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer's disease. Mol Chem Neuropathol 26: 231–245.
18. Blom E. Giedraitis V. Zetterberg H. Fukumoto H. Blennow K. Hyman B. et al. (2009) Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype. Dement Geriatr Cogn Disord 27: 458–464.
19. Braak H. Braak E. (1997) Diagnostic criteria for neuropathologic assessment of Alzheimer's disease. Neurobiol Aging 18, 85–88.
20. Brodaty H. (2006) The right to know and the right not to know: truth telling and dementia. Lecture, Congress of Alzheimer's Disease International, Berlin, 12–14 October 2006.
21. Buee L. Bussiere T. Buee-Scherrer V. Delacourte A. Hof P. (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Rev 33: 95–130.
22. de Jong D. Jansen R. Kremer B. Verbeek M. (2006) Cerebrospinal fluid amyloid β42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia. J Gerontol A Biol Sci Med Sci 61: 755–758.
23. Dermaut B. Kumar-Singh S. Engelborghs S. Theuns J. Rademakers R. Saerens J. et al. (2004) A novel presenilin 1 mutation associated with Pick's disease but not beta-amyloid plaques. Ann Neurol 55: 617–626.
24. Dubois B. Feldman H. Jacova C. de Kosky S. Barberger-Cateau P. Cummings J. et al. (2007) Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6: 734–746.
25. Engelborghs S. de Vreese K. van de Casteele T. Vanderstichele H. van Everbroeck B. Cras P. et al. (2008) Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging 29: 1143–1159.
26. Förstl H. (2003) Lehrbuch der Gerontopsychiatrie und –psychotherapie [Textbook of geriatric Psychiatry and Psychotherapy] (2nd edition). Thieme Verlag, 2, aktualis. u. erw. Aufl.
27. Galasko D. Chang L. Motter R. Clark C. Kaye J. Knopman D. et al. (1998) High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 55: 937–945.
28. Galasko D. Marder K. (2002) Picking away at frontotemporal dementia. Neurology 58: 1585–1586.
29. Glenner G. Wong C. (1984) Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 122: 1131–1135.
30. Gomez-Tortosa E. Gonzalo I. Fanjul S. Sainz M. Cantarero S. Cemillan C. et al. (2003) Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer disease. Arch Neurol 60: 1218–1222.
31. Güntert A. Döbeli H. Bohrmann B. (2006) High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience 143: 461–475.
32. Haass C. Selkoe D. (1993) Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. Cell 75:1039–1042.
33. Hampel H. Buerger K. Zinkowski R. Teipel S. Goernitz A. Andreasen N. et al. (2004) Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry 61: 95–102.
34. Hansson O. Zetterberg H. Buchhave P. Londos E. Blennow K. Minthon L. (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5: 228–234.
35. Herukka S. Hallikainen M. Soininen H. Pirttila T. (2005) CSF Abeta 42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 64: 1294–1297.
36. Hesse C. Rosengren L. Andreasen N. Davidsson P. Vanderstichele H. Vanmechelen E. et al. (2001) Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett 297: 187–190.
37. Höglund K. Hansson O. Buchhave P. Zetterberg H. Lewczuk P. Londos E. et al. (2008) Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of c-terminally truncated β-amyloid peptides. Neurodegener Dis 5: 268–276.
38. Hu Y. He S. Wang X. Duan Q. Grundke-Iqbal I. Iqbal K. et al. (2002) Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients: an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. Am J Pathol 160: 1269–1278.
39. Hulstaert F. Blennow K. Ivanoiu A. Schoonderwaldt H. Riemenschneider M. de Deyn P. et al. (1999) Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 52: 1555–1562.
40. Iqbal K. Grundke-Iqbal I. (2008). Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention. J Cell Mol Med 12: 38–55.
41. Itoh N. Arai H. Urakami K. Ishiguro K. Ohno H. Hampel H. et al. (2001) Large-scale, multicentre study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann Neurol 50: 150–156.
42. Jellinger K. Janetzki B. Attems J. Kienzl E. (2008) Biomarkers for early diagnosis of Alzheimer disease: ‘ALZheimer ASsociated gene’ – a new blood biomarker? J Cell Mol Med 12: 1094–1117
43. Jensen M. Basun H. Lannfelt L. (1995) Increased cerebrospinal fluid tau in patients with Alzheimer's disease. Neurosci Lett 186: 189–191.
44. Kanai M. Matsubara E. Isoe K. Urakami K. Nakashima K. Arai H. et al. (1998) Longitudinal study of cerebrospinal fluid levels of tau, Aβ1-40, and Aβ1-42 (43) in Alzheimer's disease: a study in Japan. Ann Neurol 44: 17–26.
45. Kanemaru K. Kameda N. Yamanouchi H. (2000) Decreased CSF amyloid beta 42 and normal tau levels in dementia with Lewy bodies. Neurology 54: 1875–1876.
46. Kang J. Lemaire H. Unterbeck A. Salbaum J. Masters C. Grzeschik K. et al. (1987) The precursor of Alzheimer's disease amyloid A 4 protein resembles a cell-surface receptor. Nature 325: 733–736.
47. Kienzl E. Jellinger K. Attems J. Janetzky B. Rattay F. Stachelberger H. et al. (2007) Neue Wege zur Früherkennung der Alzheimer Krankheit: ‘Alzheimer ASsociated Gene‘ und Biomarker im Blut [New methods for an early diagnostic detection of Alzheimer's disease: “Alzheimer Associated Gene” and serum markers]. NeuroGeriatrie 4: 61–67.
48. Kienzl E. Jellinger K. Janetzky B. Attems J. Dal-Bianco P. Stachelberger H. (2006) Nested gene and autoimmune response in Alzheimer disease. Alzheimer's Dementia 2: 205
49. Kienzl E. Jellinger K. Janetzky B. Steindl H. Bergmann J. (2002) A broader horizon of Alzheimer pathogenesis: ALZAS – an early serum biomarker? J Neural Transm Suppl 62: 87–95.
50. Klafki H. Lewczuk P. Kamrowski-Kruck H. Maler J. Müller K. Peters O. et al. (2009) Measurement of ERK 1 / 2 in CSF from patients with neuropsychiatric disorders and evidence for the presence of the activated form. J Alzheimers Dis 18: 613–622.
51. Klafki H. Staufenbiel M. Kornhuber J. Wiltfang J. (2006) Therapeutic approaches to Alzheimer's disease. Brain 129: 2840–2855.
52. Kohnken R. Buerger K. Zinkowski R. Miller C. Kerkman D. de Bernardis J. et al. (2000) Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett 287: 187–190.
53. Kosik K. Joachim C. Selkoe D. (1986) Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci U S A 83: 4044–4048.
54. Lambert J. Schraen-Maschke S. Richard F. Fievet N. Rouaud O. Berr C. et al. (2009) Association of plasma amyloid β with risk of dementia: the prospective Three-City Study. Neurology 73: 847–853.
55. Lewczuk P. Kamrowski-Kruck H. Peters O. Heuser I. Jessen F. Popp J. et al. (2010) Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Mol Psychiatry 15: 138–145.
56. Lewczuk P. Kornhuber J. Vanderstichele H. Vanmechelen E. Esselmann H. Bibl M. et al. (2008) Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study. Neurobiol Aging 29: 812–818.
57. Lewczuk P. Kornhuber J. Vanmechelen E. Peters O. Heuser I. Maier W. et al. (2010) Amyloid β peptides in plasma in early diagnosis of Alzheimer's disease: a multicenter study with multiplexing. Exp Neurol 223: 366–370.
58. Maddalena A. Papassotiropoulos A. Müller-Tillmanns B. Jung H. Hegi T. Nitsch R. et al. (2003) Cerebrospinal fluid amyloid β42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia. Arch Neurol 60: 1202–1206.
59. Marksteiner J. Kemmler G. Weiss E. Knaus G. Ullrich C. Mechtcheriakov S. et al. (2011) Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 32: 539–540.
60. Mattsson N. Brax D. Zetterberg H. (2010 a) To know or not to know: ethical issues related to early diagnosis of Alzheimer's disease. Int J Alzheimers Dis pii: 841941.
61. Mattsson N. Zetterberg H. Blennow K. (2010 b) Lessons from multicenter studies on CSF biomarkers for Alzheimer's disease. Int J Alzheimers Dis pii: 610613.
62. Mattsson N. Zetterberg H. Hansson O. Andreasen N. Parnetti L. Jonsson M. et al. (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302: 385–393.
63. Mayeux R. (1998) Evaluation and use of diagnostic tests in Alzheimer's disease. Neurobiol Aging 19: 139–143.
64. Mollenhauer B. Cepek L. Bibl M. Wiltfang J. Schulz-Schaeffer W. Ciesielczyk B. et al. (2005) Tau protein, beta-amyloid (1-42) and S100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement Cogn Geriatr Disord 19: 164–170.
65. Mollenhauer B. Cullen V. Kahn I. Krastins B. Outeiro T. Pepivani I. et al. (2008) Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 213: 315–325.
66. Mollenhauer B. Esselmann H. Trenkwalder C. Schulz-Schaeffer W. Kretzschmar H. Otto M. et al. (2011 a) CSF amyloid-β peptides in neuropathologically diagnosed dementias with Lewy bodies and Alzheimer's disease. J Alzheimers Dis 24: 383–391.
67. Mollenhauer B. Locascio J. Schulz-Schaeffer W. Sixel-Döring F. Trenkwalder C. Schlossmacher M. (2011 b) α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 10: 230–240.
68. Mollenhauer B. Steinacker P. Bahn E. Bibl M. Brechlin P. Schlossmacher M. et al. (2007) Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies. Neurodegener Dis 4:366–375.
69. Motter R. Vigo-Pelfrey C. Kholodenko D. Barbour R. Johnson-Wood K. Galasko D. et al. (1995) Reduction of beta-amyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 38: 643–648.
70. Mulder C. Scheltens P. Visser J. van Kamp G. Schutgens R. (2000) Genetic and biochemical markers for Alzheimer's disease: recent developments. Ann Clin Biochem 37: 593–607.
71. Mulugeta E. Londos E. Ballard C. Alves G. Zetterberg H. Blennow K. et al. (2011) CSF amyloid β as a novel diagnostic marker for dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 82: 160–164.
72. Neumann M. Sampathu D. Kwong L. Truax A. Micsenyi M. Chou T. et al. (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314: 130–133.
73. Olsson A. Vanderstichele H. Andreasen N. de Meyer G. Wallin A. Holmberg B. et al. (2005) Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 51: 336–345.
74. Otto M. Wiltfang J. Cepek L. Neumann M. Mollenhauer B. Steinacker P. et al. (2002) Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 58: 192–197.
75. Parnetti L. Lanari A. Amici S. Gallai V. Vanmechelen E. Hulstaert F. (2001) CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group. Neurol Sci 22: 77–78.
76. Pijnenburg Y. Schoonenboom S. Mehta P. Mehta S. Mulder C. Veerhuis R. et al. (2007) Decreased cerebrospinal fluid amyloid beta (1-40) levels in frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry 78: 735–737.
77. Portelius E. Brinkmalm G. Tran A. Andreasson U. Zetterberg H. Westman-Brinkmalm A. et al. (2010) Identification of novel N-terminal fragments of amyloid precursor protein in cerebrospinal fluid. Exp Neurol 223: 351–358.
78. Portelius E. Brinkmalm G. Tran A. Zetterberg H. Westman-Brinkmalm A. Blennow K. (2009) Identification of novel APP/Aβ isoforms in human cerebrospinal fluid. Neurodegener Dis 6: 87–94.
79. Ray S. Britschgi M. Herbert C. Takeda-Uchimura Y. Boxer A. Blennow K. et al. (2007) Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13: 1359–1362.
80. Reijn T. Rikkert M. van Geel W. de Jong D. Verbeek M. (2007) Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid beta (42) and tau proteins. Clin Chem 53: 859–865.
81. Riemenschneider M. Schmolke M. Lautenschlager N. Guder W. Vanderstichele H. Vanmechelen E. et al. (2000) Cerebrospinal beta-amyloid (1-42) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline. Neurosci Lett 284: 85–88.
82. Riemenschneider M. Wagenpfeil S. Diehl J. Lautenschlager N. Theml T. Heldmann B. et al. (2002) Tau and Aβ42 protein in CSF of patients with frontotemporal degeneration. Neurology 58: 1622–1628.
83. Seppälä T. Herukka S. Hänninen T. Tervo S. Hallikainen M. Soininen H. et al. (2010) Plasma Ab 42 and Ab 40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study. J Neurol Neurosurg Psychiatry 81: 1123–1127.
84. Shaw L. Vanderstichele H. Knapik-Czajka M. Figurski M. Coart E. Blennow K. et al. (2011) Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol 121: 597–609.
85. Shoji M. Kanai M. (2001) Cerebrospinal fluid Aβ40 and Aβ42: natural course and clinical usefulness. J Alzheimers Dis 25: 273–281.
86. Shoji M. Matsubara E. Kanai M. Ikeda M. Harigaya Y. Okamoto K. et al. (2000) Taps to Alzheimer's patients: a continuous Japanese study of cerebrospinal fluid biomarkers. Ann Neurol 48: 402.
87. Shoji M. Matsubara E. Kanai M. Watanabe M. Nakamuro T. Tomidokoro Y. et al. (1998) Combination assay of CSF tau, Aβ1-40 and Aβ1-42 (43) as a biochemical marker of Alzheimer's disease. J Neurol Sci 158: 134–140.
88. Sjögren M. Davidsson P. Tullberg M. Minthon L. Wallin A. Wikkelso C. et al. (2001) Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry 70: 624–630.
89. Sjögren M. Minthon L. Davidson P. Granerus A. Clarberg A. Vanderstichele H. et al. (2000 a) CSF levels of tau, β-amyloid1-42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm 107: 563–579.
90. Sjögren M. Rosgren L. Minthon L. Davidson P. Blennow K. Wallin A. (2000 b) Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology 54: 1960–1964.
91. Soares H. Chen Y. Sabbag M. Roher A. Schrijvers E. Breteler M. (2009) Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels. Ann N Y Acad Sci 1180: 56–67
92. Solfrizzi V. D'Introno A. Colacicco A. Capurso C. Todarello O. Pellicani V. et al. (2006) Circulating biomarkers of cognitive decline and dementia. Clin Chim Acta 364: 91–112.
93. Spitzer P. Klafki H. Blennow K. Buee L. Esselmann H. Herukka S. et al. (2010) cNEUPRO: novel biomarkers for neurodegenerative diseases. Int J Alzheimers Dis pii: 548145.
94. Steinacker P. Hendrich C. Sperfeld A. Jesse S. Lehnert S. Pabst A. et al. (2009) Concentrations of beta-amyloid precursor protein processing products in cerebrospinal fluid of patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration. J Neural Transm 116: 1169–1178.
95. Steinacker P. Hendrich C. Sperfeld A. Jesse S. von Arnim C. Lehnert S. et al. (2008) TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Arch Neurol 65: 1481–1487.
96. Steinacker P. Klafki H. Lehnert S. Jesse S. Arnim C. Tumani H. et al. (2010) ERK 2 is increased in cerebrospinal fluid of Creutzfeldt-Jakob disease patients. J Alzheimers Dis 22: 119–128.
97. Steinacker P. Mollenhauer B. Bibl M. Cepek L. Esselmann H. Brechlin P. et al. (2004) Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases. Neurosci Lett 370: 36–39.
98. Strittmatter W. Weisgraber K. Huang D. Dong L. Salvesen G. Pericak-Vance M. et al. (1993) Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset alzheimer disease. Proc Natl Acad Sci U S A 90: 8098–8102.
99. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. (1998) The Working Group on: ‘Molecular and Biochemical Markers of Alzheimer's Disease’, Consensus report of the Working Group on: ‘Molecular and Biochemical Markers of Alzheimer's Disease’. Neurobiol Aging 19: 109–116.
100. Vanderstichele H. de Meyer G. Andreasen N. Kostanjevecki V. Wallin A. Olsson A. et al. (2005) Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment. Clin Chem 51: 1650–1660.
101. Vanmechelen E. Vanderstichele H. Davidsson P. van Kerschaver E. van der Perre B. Sjogren M. et al. (2000) Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 285: 49–52.
102. Vanmechelen E. van Kerschaver E. Blennow K. de Deyn P. Gartner F. Parnetti L. et al. (2001) CSF-Phospho-tau (181P) as a promising marker for discriminating Alzheimer's disease from dementia with Lewy bodies. In: Ed. Iqbal K. Sisodia S. Winblad B. (eds), Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics. Chichester: John Wiley and Sons, pp. 285–291.
103. van Oijen M. Hofmann A. Soares H. Koudstaal P. Breeteler M. (2006) Plasma Aβ1-40 and Aβ1-42 and the risk of dementia: a prospective case-cohort study. Lancet Neurol 5: 655–660.
104. Vigo-Pelfrey C. Seubert P. Barbour R. Blomquist C. Lee M. Lee D. et al. (1995) Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. Neurology 45: 788–793.
105. Watt A. Perez K. Faux N. Pike K. Rowe C. Bourgeat P. et al. (2010) Increasing the predictive accuracy of amyloid-β blood-borne biomarkers in Alzheimer's disease. J Alzheimers Dis 23: 1–13.
106. Welge V. Fiege O. Lewczuk P. Mollenhauer B. Esselmann H. KLafki H. et al. (2009) Combined CST tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease. J Neural Transm 116: 203–212.
107. Wiltfang J. Esselmann H. Bibl M. Hüll M. Hampel H. Kessler H. et al. (2007) Amyloid β peptide ratio 42 / 40 but not Aβ42 correlates with phospho-Tau in patients with low- and high-CSF Aβ40 load. J Neurochem 101: 1053–1059.
108. Wiltfang J. Esselmann H. Bibl M. Smirnov A. Otto M. Paul S. et al. (2002) Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J Neurochem 81: 481–496.
109. Wiltfang J. Esselmann H. Smirnov A. Bibl M. Cepek L. Steinacker P. et al. (2003) Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Ann Neurol 54: 263–267.
110. Zekanowski C. Golan M. Krzysko K. Lipczynska-Lojkowska W. Filipek S. Kowalska A. et al. (2006) Two novel presenilin 1 gene mutations connected with frontotemporal dementia-like clinical phenotype: genetic and bioinformatic assessment. Exp Neurol 200: 82–88.
111. Zetterberg H. Andreasson U. Hansson O. Wu G. Sankaranarayanan S. Andersson M. et al. (2008) Elevated cerebrospinal fluid BACE 1 activity in incipient Alzheimer disease. Arch Neurol 65: 1102–1107.
112. Zhong Z. Ewers M. Teipel S. Bürger K. Wallin A. Blennow K. et al. (2007) Levels of β-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry 64: 718–726.